Lv7
4470 积分 2023-01-12 加入
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
24天前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression and ultralow expression of HER-2 (2025 edition)]
26天前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression and ultralow expression of HER-2 (2025 edition)]
26天前
已关闭
A comprehensive review of immune checkpoint inhibitors for cancer treatment
1个月前
已完结
HER2-positive gastroesophageal cancer: meaningful progress, unresolved biology
1个月前
已关闭
Chinese expert consensus on hematologic malignancy karyotyping
1个月前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
1个月前
已完结
Bevacizumab plus erlotinib in advanced solid cancers with Krebs cycle gene mutations: A multicenter phase II study (BRISK; KCSG AL22-16)
1个月前
已完结
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2 -Driven Tumors
1个月前
已关闭
Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer
1个月前
已完结
皖公网安备34019202002308
